- Home
- PSX vs TAK Comparison
PSX vs TAK Comparison
Compare PSX & TAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PSX | TAK |
|---|---|---|
| Founded | 1875 | 1781 |
| Country | United States | Japan |
| Employees | N/A | 47455 |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 62.8B | 56.6B |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | PSX | TAK |
|---|---|---|
| Price | $175.84 | $18.73 |
| Analyst Decision | Buy | |
| Analyst Count | 19 | 0 |
| Target Price | ★ $155.74 | N/A |
| AVG Volume (30 Days) | ★ 3.4M | 2.7M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.89% | 2.81% |
| EPS Growth | ★ 116.23 | N/A |
| EPS | ★ 10.79 | N/A |
| Revenue | ★ $132,376,000,000.00 | N/A |
| Revenue This Year | $3.33 | $0.04 |
| Revenue Next Year | $0.90 | $0.92 |
| P/E Ratio | ★ $16.26 | $41.25 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $91.01 | $12.99 |
| 52 Week High | $190.61 | $18.90 |
Technical Indicators
Market Signals| Indicator | PSX | TAK |
|---|---|---|
| Relative Strength Index (RSI) | 54.58 | 60.97 |
| Support Level | $127.98 | $17.65 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 5.99 | 0.27 |
| MACD | -0.89 | 0.05 |
| Stochastic Oscillator | 24.45 | 84.30 |
Price Performance
Historical ComparisonAbout PSX Phillips 66
Phillips 66 is an independent refiner that owns or holds interest in 10 refineries with a total crude throughput capacity of 1.9 million barrels per day, or mmb/d, at the end of 2025. The midstream segment comprises extensive transportation and NGL processing assets. It includes 70,000 miles of crude oil, refined petroleum product, NGL and natural gas pipeline systems, and a comprehensive set of refined petroleum product, NGL and crude oil terminals, gathering and processing plants and fractionation facilities and various other storage and loading facilities. Its CPChem chemical joint venture operates facilities primarily in the United States and the Middle East and produces olefins and polyolefins.
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.